… structured information provided by the trial investigators on a form designed for this prospective
meta-analysis. Summary … ; this Letter serves as a summary of the key elements of the full …

… due to COVID-19 pneumonia will be considered eligible. Potential candidates will be identified
and consecutively included in the emergency room or in the COVID-19 admission wards …

… the COVID-19 pandemic. This was an open label dose escalation study of REALIST ORBCEL-C
in patients with ARDS. The COVID-19 … the Phase 2 trial as a COVID-19 specific trial. This …

… for people with ongoing COVID-19 sequelae more than three months after hospital discharge.
… Adults with ongoing COVID-19 sequelae more than three months after hospital discharge …

… In this study, patients with confirmed positive COVID-19 tests receive imatinib for a total of
14 days; 400 mg orally daily Days 1-14. Imatinib 400 mg tablets will be encapsulated using …

… Participants are non-hospitalised adults with highly suspected COVID-19 within the first 5
days of symptom onset, or who have tested positive with SARS-CoV-2 causing COVID-19 …

Objectives The primary aim of the present study is to examine the efficacy of an online
intervention for poor sleep in the context of an ongoing stressful major life event, by assessing if …

… of Famotidine on the recovery process of COVID-19 patients. … of the National Committee of
COVID-19 and oral famotidine 160 … Committee of COVID-19 and placebo in the same dosage. …

… /or the severity of COVID-19 and other infectious diseases in … to illness among HCW during
the COVID-19 pandemic. The … among HCW during the COVID-19 pandemic. Hypothesis: …

… COVID-19 infection. Confirmed cases will be evaluated and compared with those patients
who did not have COVID-19 … that would arise if only COVID-19 patients were independently …